Analyzing TMO Stock – Market Insights

By Susan Ramirez • Wednesday, April 02 09:53 • Permanent Link

Large-cap Industrials company Thermo Fisher Scientific has moved -0.1% so far today on a volume of 307,120, compared to its average of 1,936,551. In contrast, the S&P 500 index moved -0.0%.

Thermo Fisher Scientific trades -26.76% away from its average analyst target price of $659.08 per share. The 28 analysts following the stock have set target prices ranging from $560.77 to $767.0, and on average have given Thermo Fisher Scientific a rating of buy.

If you are considering an investment in TMO, you'll want to know the following:

Thermo Fisher Scientific's current price is 135.9% above its Graham number of $204.63, which implies that at its current valuation it does not offer a margin of safety
Thermo Fisher Scientific has moved -16.2% over the last year, and the S&P 500 logged a change of 8.1%
Based on its trailing earnings per share of 16.52, Thermo Fisher Scientific has a trailing 12 month Price to Earnings (P/E) ratio of 29.2 while the S&P 500 average is 29.3
TMO has a forward P/E ratio of 20.5 based on its forward 12 month price to earnings (EPS) of $23.49 per share
Its Price to Book (P/B) ratio is 3.71 compared to its sector average of 3.2
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
Based in Waltham, the company has 125,000 full time employees and a market cap of $182.1 Billion. Thermo Fisher Scientific currently returns an annual dividend yield of 0.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.